NO20020571L - Peptider som blokkerer infeksjonsevnen, og fremgangsmåter for anvendelse av disse - Google Patents

Peptider som blokkerer infeksjonsevnen, og fremgangsmåter for anvendelse av disse

Info

Publication number
NO20020571L
NO20020571L NO20020571A NO20020571A NO20020571L NO 20020571 L NO20020571 L NO 20020571L NO 20020571 A NO20020571 A NO 20020571A NO 20020571 A NO20020571 A NO 20020571A NO 20020571 L NO20020571 L NO 20020571L
Authority
NO
Norway
Prior art keywords
peptides
methods
infection
infectivity
block infectivity
Prior art date
Application number
NO20020571A
Other languages
English (en)
Other versions
NO20020571D0 (no
Inventor
Anders Vahlne
Original Assignee
Tripep Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tripep Ab filed Critical Tripep Ab
Publication of NO20020571D0 publication Critical patent/NO20020571D0/no
Publication of NO20020571L publication Critical patent/NO20020571L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/915—Therapeutic or pharmaceutical composition
    • Y10S977/916—Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Oppdagelsen av peptider i amid form som inhiberer virusinfeksjonsevne, innbefattet infeksjon med humant immundefisient virus (HTV), beskrives. Fremgangsmåter for anvendelse av peptider beskrives også, innbefattet anvendelse i medikamenter for behandling og forebyggelse av virusinfeksjon, for eksempel HIV-infeksjon.
NO20020571A 1999-08-09 2002-02-05 Peptider som blokkerer infeksjonsevnen, og fremgangsmåter for anvendelse av disse NO20020571L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/370,368 US6258932B1 (en) 1999-08-09 1999-08-09 Peptides that block viral infectivity and methods of use thereof
PCT/IB2000/000961 WO2001010456A2 (en) 1999-08-09 2000-06-29 Peptides that block viral infectivity and methods of use thereof

Publications (2)

Publication Number Publication Date
NO20020571D0 NO20020571D0 (no) 2002-02-05
NO20020571L true NO20020571L (no) 2002-04-05

Family

ID=23459335

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20020571A NO20020571L (no) 1999-08-09 2002-02-05 Peptider som blokkerer infeksjonsevnen, og fremgangsmåter for anvendelse av disse

Country Status (15)

Country Link
US (2) US6258932B1 (no)
EP (1) EP1206273A2 (no)
JP (1) JP2003506410A (no)
KR (1) KR20020025970A (no)
CN (1) CN1377275A (no)
AU (1) AU5700800A (no)
CA (1) CA2378460A1 (no)
CZ (1) CZ2002402A3 (no)
HU (1) HUP0202502A2 (no)
IL (1) IL147969A0 (no)
IS (1) IS6262A (no)
MX (1) MXPA02001344A (no)
NO (1) NO20020571L (no)
PL (1) PL354090A1 (no)
WO (1) WO2001010456A2 (no)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA02001349A (es) * 1999-08-09 2002-07-22 Tripep Ab Inhibidores de la polimerizacion de proteinas y metodos de uso.
FR2827170B1 (fr) * 2001-07-13 2004-07-16 Soc Extraction Principes Actif Utilisation de peptides pour augmenter l'adhesion cellulaire
US6593455B2 (en) * 2001-08-24 2003-07-15 Tripep Ab Tripeptide amides that block viral infectivity and methods of use thereof
US6455670B1 (en) * 2001-09-06 2002-09-24 Tripep Ab Pentamer peptide amide, ALGPG-NH2, that inhibits viral infectivity and methods of use thereof
EP1436317A1 (en) * 2001-09-19 2004-07-14 Tripep Ab Molecules that block viral infectivity and methods of use thereof
MXPA04003773A (es) * 2001-10-22 2004-07-30 Amgen Inc Uso de leptina para tratar lipoatrofia humana y metodo para determinar la predisposicion a dicho tratamiento.
AU2003231012B2 (en) * 2002-04-22 2008-05-08 University Of Maryland, Baltimore County Antiviral inhibitions of capsid proteins
WO2003091275A2 (en) * 2002-04-23 2003-11-06 Andrea Savarino Compositions containing anti-hiv peptides and methods of use
US20050096319A1 (en) * 2003-02-21 2005-05-05 Balzarini Jan M.R. Identification of compounds that inhibit replication of human immunodeficiency virus
KR20050101221A (ko) * 2003-02-21 2005-10-20 트리펩 아베 Ｈｉｖ 복제의 억제를 위한 글리신아미드 유도체
DE102005015005A1 (de) * 2005-04-01 2006-10-05 Qiagen Gmbh Verfahren zur Behandlung einer Biomoleküle enthaltenden Probe
TWI457136B (zh) 2005-04-04 2014-10-21 Tibotec Pharm Ltd Ｈｉｖ-感染之預防
JP2009523157A (ja) * 2006-01-13 2009-06-18 オンコレー アーベー 虚血および神経変性の処置のための化合物
CA2637600A1 (en) 2006-01-17 2007-07-26 Health Research, Inc. Heteroduplex tracking assay
US20100093867A1 (en) * 2006-07-05 2010-04-15 Ryoichi Matsuda Method Of Treating Genetic Disease Caused By Nonsense Mutation
EP2170364A2 (en) * 2007-06-25 2010-04-07 Oncoreg AB Tpp ii inhibitors for use in the treatment of autoimmune and inflammatory diseases and transplant rejection
CA2730064A1 (en) 2008-08-08 2010-02-11 Asim Kumar Debnath Small molecule inhibitors of retroviral assembly and maturation
CN101845079B (zh) * 2009-03-27 2014-04-09 中国人民解放军军事医学科学院毒物药物研究所 六肽或其衍生物及其医药用途
JP5664992B2 (ja) * 2009-08-26 2015-02-04 国立大学法人名古屋大学 細胞特異的ペプチド及びその用途
PT2621519T (pt) 2010-09-28 2017-10-04 Aegerion Pharmaceuticals Inc Polipéptido de fusão de leptina-abd com duração de ação melhorada
NZ611176A (en) 2010-12-02 2015-07-31 Bionor Immuno As Peptide scaffold design
EP2913338A1 (en) * 2014-02-28 2015-09-02 Roche Diagniostics GmbH Soluable and immunoreactive variants of HTLV capsid antigen p24
US12016844B2 (en) 2019-07-02 2024-06-25 Virago Vax Inc. Mammary tumor virus suppression
US12029783B2 (en) * 2019-07-02 2024-07-09 Virago Vax Inc. Mammary tumor virus vaccine
CN111116717B (zh) * 2020-01-03 2021-10-29 中国科学院大学温州研究院(温州生物材料与工程研究所) 含有n-甲基-d-葡糖胺单元的糖肽水凝胶、制备方法及其应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4215112A (en) * 1979-03-14 1980-07-29 Ortho Pharmaceutical Corporation Tripeptides and methods
US4658013A (en) * 1981-07-28 1987-04-14 Sterling Drug Inc. Analgesic and/or opiate antagonist tripeptide amides and processes for preparation and compositions thereof
US4818540A (en) 1985-02-25 1989-04-04 Rutgers, The State University Of New Jersey Transdermal fertility control system and process
US4612337A (en) 1985-05-30 1986-09-16 The Trustees Of Columbia University In The City Of New York Method for preparing infection-resistant materials
US4952411A (en) 1987-02-25 1990-08-28 Trustees Of Columbia University In The City Of New York Method of inhibiting the transmission of AIDS virus
US4950647A (en) * 1988-10-04 1990-08-21 Nucleic Acid Research Institute T cell immunopotentiator
IT1231342B (it) 1989-08-28 1991-11-28 Prodotti Antibiotici Spa Derivati peptidici farmacologicamente attivi e preparazioni farmaceutiche che li contengono
DE4014655A1 (de) * 1990-05-08 1991-11-14 Behringwerke Ag Peptidamide, verfahren zu deren herstellung und diese enthaltende mittel als fibrin/thrombin-gerinnungsinhibitoren
US5346989A (en) * 1990-08-22 1994-09-13 Syntello Vaccine Development Kb Peptides for use in induction of T cell activation against HIV-1
US5627035A (en) 1990-08-22 1997-05-06 Syntello Vaccine Development Ab Peptides that block human immunodeficiency virus and methods of use thereof
GB9024129D0 (en) * 1990-11-06 1990-12-19 Thrombosis Research Trust Inhibitors and substrates of thrombin
AU2140592A (en) 1991-05-17 1992-12-30 Chiron Corporation Inhibitor of nf-kappa b transcriptional activator and uses thereof
NZ280932A (en) * 1995-02-07 1996-12-20 Mitsui Toatsu Chemicals Soil fumigant preparations; stick-shaped device comprising a water-soluble and/or biodegradable film incorporating a soil steriliser and/or a nematocide; ribbon and net shaped preparations; herbicide containing chloropicrin
US5817626A (en) * 1995-03-14 1998-10-06 Praecis Pharmaceuticals Incorporated Modulators of beta-amyloid peptide aggregation
US5770620A (en) * 1995-06-19 1998-06-23 Ontogen Corporation Aryl acrylic acid derivatives useful as protein tyrosine phosphatase inhibitors
US5872210A (en) * 1995-10-05 1999-02-16 The United States Of America As Represented By The Department Of Health And Human Services Transframe peptide inhibitor of viral protease
WO1997037228A1 (en) * 1996-03-29 1997-10-09 The Trustees Of Boston University Methods for diagnosing and treating alzheimer's disease
US6126939A (en) 1996-09-03 2000-10-03 Yeda Research And Development Co. Ltd. Anti-inflammatory dipeptide and pharmaceutical composition thereof
WO1998035062A1 (en) * 1997-02-07 1998-08-13 Lingappa Jaisri R Multistep, atp-dependent cell-free system for the assembly of human immunodeficiency virus capsids
US5843995A (en) 1997-07-07 1998-12-01 University Of Medicine And Dentistry Of New Jersey Inhibition of HIV-1 replication using oligocarbamate derivatives
AU8912698A (en) 1997-08-19 1999-03-08 University Of Medicine And Dentistry Of New Jersey Inhibition of hiv-1 replication using d-amino acid peptides
WO2000009158A1 (en) * 1998-08-12 2000-02-24 University Of Virginia Patent Foundation Assay for assembly of herpes simplex virus capsid
US6455670B1 (en) * 2001-09-06 2002-09-24 Tripep Ab Pentamer peptide amide, ALGPG-NH2, that inhibits viral infectivity and methods of use thereof

Also Published As

Publication number Publication date
HUP0202502A2 (hu) 2002-11-28
IS6262A (is) 2002-02-08
JP2003506410A (ja) 2003-02-18
IL147969A0 (en) 2002-09-12
EP1206273A2 (en) 2002-05-22
KR20020025970A (ko) 2002-04-04
CA2378460A1 (en) 2001-02-15
CN1377275A (zh) 2002-10-30
AU5700800A (en) 2001-03-05
MXPA02001344A (es) 2002-07-22
CZ2002402A3 (cs) 2002-09-11
WO2001010456A3 (en) 2001-09-20
US20020091086A1 (en) 2002-07-11
WO2001010456A2 (en) 2001-02-15
PL354090A1 (en) 2003-12-29
NO20020571D0 (no) 2002-02-05
US6258932B1 (en) 2001-07-10

Similar Documents

Publication Publication Date Title
NO20020571L (no) Peptider som blokkerer infeksjonsevnen, og fremgangsmåter for anvendelse av disse
ATE264914T1 (de) Antivirale proteine, dafür kodierende dna, und deren verwendung
FR16C0028I2 (fr) Vecteurs viraux et utilisation de ces derniers dans des methodes therapeutiques
TR199903053T2 (xx) Benzimidazol t�revleri.
EA200000840A1 (ru) Антивирусные производные пиримидина
DE60216151D1 (de) Langwirkende Fusionspeptidinhibitoren gegen HIV-Infektion
MD960172A (en) 5,6-dihydropyrone derivatives as proteaze inhibitors and antiviral agents
ATE374208T1 (de) Pharmakologisch aktive antivirale peptide und methoden zu ihrer anwendung
EA199800526A1 (ru) Производные бензимидазола и их применение для лечения вирусных инфекций
DK0777669T3 (da) 4-[2-amino-6-(cyclopropylamino)-9H-purin-yl]-2-cyclopenten-1-methanolsuccinat som antiviralt middel
MX9700414A (es) Agentes antivirales de difluoroestatona.
ES2159287T3 (es) Peptidos hemorreguladores.
DE60006519D1 (de) Glutathion-reduktase zur behandlung und prophylaxe von aids
UA41338C2 (uk) Спосіб інгібування ретровірусної інфекції, яка викликана вірусом імунодефіциту людини (віл), спосіб інгібування вірусу імунодефіциту людини (віл)
HUP0100937A2 (hu) Többszörösen elágazó peptidkonstrukciókat tartalmazó liposzómák és alkalmazásuk humán immundeficiencia vírus ellen
DK0545991T3 (da) Peptider, der blokerer infektioner med human immundefektvirus, og fremgangsmåder til anvendelse deraf
ATE306275T1 (de) Pharmazeutische zubereitungen zur behandlung von dns viraler infektionen, welche ein schleifendiureticum und lithium enthalten
AP9801368A0 (en) Benzamide treatment of mentia associated with HIV AIDS VIRUS (HIV-1) infection
ATE198602T1 (de) Makrocyclische difluorostatonderivate als antivirale mittel
Hecht A new focus on primary HIV infection
HRP20030701A2 (en) Natural antibodies active against hiv virus

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application